Twan Lammers

Sep 6, 2024 | nature.com | Paul Joyce |María José Alonso |Michelle S. Bradbury |Maria Kavallaris |Robert LANGER |Twan Lammers | +7 more

AbstractNanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding of nanomedicines’ physicochemical properties, limited exposure in the cell or tissue of interest, poor reproducibility of preclinical outcomes in clinical trials, and biocompatibility concerns.

Feb 15, 2024 | onlinelibrary.wiley.com | Twan Lammers

Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules more efficiently to pathological sites and by attenuating their accumulation in healthy organs and tissues, nanomedicine formulations aim to improve the balance between drug efficacy and toxicity. More than 20 cancer nanomedicines are approved for clinical use, and 100′s of formulations are in (pre)clinical development.